Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: Results from the GO-FORWARD study

Arthritis Research and Therapy

Volumn 12, Issue 6, 2010, Pages

  Visvanathan, Sudha ^a,i   Rahman, Mahboob U ^a,b,j   Keystone, Edward ^c,d   Genovese, Mark ^e   Klareskog, Lars ^f,l   Hsia, Elizabeth ^a,b   Mack, Michael ^a   Buchanan, Jacqui ^g,k   Elashoff, Michael ^h   Wagner, Carrie ^a  

^a CENTOCOR INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e STANFORD UNIVERSITY   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g Johnson and Johnson Pharmaceutical Services   (United States)

^h Elashoff Consulting   (United States)

ⁱ HOFFMANN LA ROCHE INC   (United States)

^j PFIZER INC   (United States)

^k Buchanan Biotech Consulting   (United States)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN E3; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CD40 ANTIGEN; CXCL1 CHEMOKINE; FERRITIN; GOLIMUMAB; HAPTOGLOBIN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 16; INTERLEUKIN 6; LIPOPROTEIN A; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; MYOGLOBIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDINOLINE; SERUM AMYLOID P; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; VON WILLEBRAND FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; METHOTREXATE;

EID: 78349301672     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3188     Document Type: Article

References (30)

1. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001, 60:924-927. 10.1136/ard.60.10.924, 1753390, 11557647.
2. Listing J, Rau R, Muller B, Alten R, Gromnica-Ihle E, Hagemann D, Zink A. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J Rheumatol 2000, 27:2100-2109.
3. Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DM, van der Linden S, Boers M. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006, 54:1772-1777. 10.1002/art.21896, 16736519.
4. Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710. 10.1002/art.21678, 16508926.
5. Semmler M, Seeck U, Neustadt B, Schulz M, Dotzlaw H, Neeck G, Eggert M. No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. Clin Rheumatol 2007, 26:1499-1504. 10.1007/s10067-007-0540-2, 17273811.
6. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002, 61:311-318. 10.1136/ard.61.4.311, 1754066, 11874832.
7. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915. 10.1056/NEJMoa035075, 14614165.
8. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:35-39. 10.1136/ard.2005.038851, 1797988, 15975966.
9. Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006, 8:R3. 10.1186/ar1851, 1526573, 16356192.
10. Trocmé C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, Miossec P, Tebib J, Berger F, Nissen MJ, Juvin R, Morel F, Gaudin P. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333. 10.1136/ard.2008.093153, 2921545, 18664547.
11. Dwivedi RC, Dhindsa N, Krokhin OV, Cortens J, Wilkins JA, El-Gabalawy HS. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res Ther 2009, 11:R32. 10.1186/ar2637, 2688177, 19265537.
12. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol 2009, 36:1371-1379. 10.3899/jrheum.080755, 19487269.
13. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009, 68:789-796. 10.1136/ard.2008.099010, 2674549, 19066176.
14. Rules Based Medicine. , http://www.rulesbasedmedicine.com/
15. Genovese MC, Keystone EC, Hsia EC, Buchanan J, Klareskog L, Murphy F, Wu Z, Parasuraman S, Rahman MU. Golimumab significantly improves physical function, health-related quality of life, and fatigue in rheumatoid arthritis patients: results from the GO-FORWARD study. Arthritis Rheum 2009, 58:S553.
16. Milman N, Karsh J, Booth RA. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem 2010, 43:1309-1314. 10.1016/j.clinbiochem.2010.07.012, 20655893.
17. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009, 60:2870-2879. 10.1002/art.24802, 2828490, 19790070.
18. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, Foell D, Sorg C, Sunderkotter C, Roth J. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003, 48:2622-2626. 10.1002/art.11177, 13130482.
19. Miltenburg AM, van Laar JM, de Kuiper R, Daha MR, Breedveld FC. Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation. Br J Rheumatol 1991, 30:186-189. 10.1093/rheumatology/30.3.186, 2049578.
20. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, Limburg PC. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994, 21:425-429.
21. Warstat K, Hoberg M, Rudert M, Tsui S, Pap T, Angres B, Essl M, Smith TJ, Cruikshank WW, Klein G, Gay S, Aicher WK. Transforming growth factor beta1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. Ann Rheum Dis 2010, 69:270-275. 10.1136/ard.2008.091116, 19279017.
22. Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology (Oxford) 1999, 38:714-720. 10.1093/rheumatology/38.8.714, 10501417.
23. Weisser J, Rahfoth B, Timmermann A, Aigner T, Brauer R, von der Mark K. Role of growth factors in rabbit articular cartilage repair by chondrocytes in agarose. Osteoarthritis Cartilage 2001, 9:suppl A:S48-S54.
24. Trebec-Reynolds DP, Voronov I, Heersche JN, Manolson MF. VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha. J Cell Biochem 2010, 110:343-351.
25. Ahn JK, Koh EM, Cha HS, Lee YS, Kim J, Bae EK, Ahn KS. Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 2008, 47:834-839. 10.1093/rheumatology/ken086, 18400834.
26. Nemec P, Pavkova-Goldbergova M, Gatterova J, Vasku A, Soucek M. Association of the 5A/6A promoter polymorphism of the MMP-3 gene with the radiographic progression of rheumatoid arthritis. Ann N Y Acad Sci 2007, 1110:166-176. 10.1196/annals.1423.019, 17911432.
27. Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo-Repo M. Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum 1991, 34:815-821. 10.1002/art.1780340706, 2059229.
28. Emlen W, Niebur J, Flanders G, Rutledge J. Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity. J Rheumatol 1996, 23:974-978.
29. Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R76. 10.1186/ar2706, 2714123, 19460157.
30. Teixeira VH, Olaso R, Martin-Magniette ML, Lasbleiz S, Jacq L, Oliveira CR, Hilliquin P, Gut I, Cornelis F, Petit-Teixeira E. Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients. PLoS One 2009, 4:e6803. 10.1371/journal.pone.0006803, 2729373, 19710928.